Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tech Transfer Roundup: Aduro Hopes Stanford Algorithm Will Optimize Its IO Candidates

Executive Summary

Aduro Biotech discusses what it looks for in an academic collaboration. Plus, Sarepta adds gene therapies to its Duchenne pipeline from Nationwide Children's Hospital and Columbia University out-licenses IP to a pair of biotechs.

You may also be interested in...



Finance Watch: Ayala Launches First Biopharma IPO In May

The cancer drug developer raised $55m. Also, Lyra raised $56m in the last of four biopharma IPOs in April, Biogen sold $3bn worth of debt, Oberland raised a $1.05bn fund and Praxis launched with more than $100m. 

Aduro Says End Of Janssen Collaborations “Not A Lethal Blow”

Both Janssen and Aduro gradually realized the Listeria technology platform was not delivering hoped-for results. Aduro will not continue the projects abandoned by Janssen, and will focus on its STING and APRIL programs going forward.

Keeping Track: Tpoxx Wins Green Light For Smallpox, Submissions Galore, And A Broader Approval For Xtandi

The latest drug development news and highlights from our US FDA Performance Tracker.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC098187

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel